Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Date:6/30/2008

rently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
2. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
5. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
6. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
7. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
8. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Pa. , April 1, 2015  Pittman ... the introduction of PLG24, PLG42K, PLG42S, PLG52, and ... with Pittman brush and brushless DC motors and ... The new products add 35 standard motor-gearbox family ... PLG planetary gearboxes deliver high torque loads with ...
(Date:4/1/2015)... and MOUNTAIN VIEW, Calif. ... (NYSE: BSX ) announces that it has ... a venture-backed medical device company that develops, manufactures ... (EUS) guided transluminal drainage of targeted areas within ... close this week. The Xlumena ...
(Date:4/1/2015)... ASPEN, Colo. , April 1, 2015 /PRNewswire/ ... Foundation (CKF), is pleased to sponsor the second annual ... the award, which will recognize two transplant recipients who ... is a career accomplishment, participation in a sport or ... and loved ones. "The Bounce Back ...
Breaking Medicine Technology:Pittman Motors Expands PLG Planetary Gearbox Offering 2Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3
... Sept. 21 The Association of Medical Media (AMM) ... highest-scoring medical journal advertisements Thursday, September 16, 2010.   ... annual study developed by AMM, researches physician attitudes toward ... 21 specialties from the 86 most widely-advertised products in ...
... More than one in three diabetes patients skip doses ... they have done so on average three times in the ... reality this number could be as high as six doses*, ... Insulin Therapy (GAPP™) survey, released today by Novo Nordisk. ...
Cached Medicine Technology:AMM Names 2010 Doctors' Choice Awards Winners 2AMM Names 2010 Doctors' Choice Awards Winners 3New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 2New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 3
(Date:4/1/2015)... EAGAN, Minn. (April 1, 2015) —Blue Cross and ... (Blue Cross) today announced audited financial results for 2014. ... of $61.5 million, reflecting positive investment portfolio performance that ... operating loss of $8.2 million on full-year revenues of ... of one percent (0.1%). , Blue Cross reported ...
(Date:4/1/2015)... 2015 Dr Roz Kamani, a Vancouver ... now offering her patients an opportunity to learn more ... in “Beauty Days”, which is an exclusive VIP event ... Kitsilano Skin Care Clinic. It is attended by Dr ... the latest products and services that are on offer. ...
(Date:4/1/2015)... Ill. (PRWEB) April 01, 2015 OSF ... OSF Healthcare System , was welcomed into the ... Ceremony officiated by Msgr. Paul E. Showalter, vicar general ... The Blessing and Dedication culminated a nearly year-long transition ... eleventh OSF HealthCare hospital. Speakers for the morning ceremony ...
(Date:4/1/2015)... 01, 2015 Like a mosaic slowly ... scientific understanding of the potential causes of rosacea. April ... National Rosacea Society (NRS) to educate the public on ... disorder now estimated to affect more than 16 million ... research on rosacea through its patient-funded research grants program, ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 eMindful ... the expansion of its executive team with the addition ... digital officer. , In his new role, ... and user interface across the business and consumer portals. ... and building the company’s online community. His hiring ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 2Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 3
... just one of two gene copies inherited from either parent. ... from one parent, called a "hemizygous" deletion, can contribute to ... a professor in the Department of Genetics at Harvard Medical ... an answer. The most common hemizygous deletions in cancer, their ...
... UC Irvine immunologist will receive $4.8 million to create a ... to treat multiple sclerosis. The California Institute for Regenerative ... of the Sue & Bill Gross Stem Cell Research Center ... board gave 21 such grants worth $69 million to 11 ...
... is involved in removing beta-amyloid, the main Alzheimer,s-causing substance in ... that this may apply in humans. Researchers at ... with colleagues in the National Institute on Aging in the ... of genes in blood samples from nearly 700 people. The ...
... coated with colloidal silver, which prevents the growth of ... the filter. Other metals such as copper and zinc ... from Princeton University in New Jersey used atomic force ... Escherichia coli ( E. coli ) bacteria ...
... Feola, a University of Kentucky College of Pharmacy faculty ... received a five-year, $1.8 million grant from the National ... immune responses in the lungs that will potentially lead ... cystic fibrosis and other chronic pulmonary inflammatory conditions. ...
... , THURSDAY, May 24 (HealthDay News) -- Morbidly obese patients ... of developing complications and also face higher hospital costs, a ... common operation for spinal pain. People with a body mass ... obese. They are generally 50 to 100 percent over their ...
Cached Medicine News:Health News:Cancer may require simpler genetic mutations than previously thought 2Health News:Cancer may require simpler genetic mutations than previously thought 3Health News:UCI stem cell researcher to receive $4.8 million in state funding 2Health News:Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis 2Health News:Severely Obese Have More Complications With Spinal Surgery 2
Gynecomastia Vest...
Male Compression Vest, Front Closure...
Female Mini-VEST, Front Closure, X-Firm...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Medicine Products: